HIV Therapy in Development at American Gene Technologies - A Non-Technical Overview
CEO of American Gene Technologies Jeff Galvin provides a non-technical overview of how AGT's HIV therapy is intended to work. For more information about American Gene Technologies HIV research, visit: https://www.americangene.com/pipeline...
If you liked this video, please subscribe to this Youtube channel here: / @americangenetechnologies
About Jeff Galvin:
Jeff Galvin is the CEO and Co-founder of American Gene Technologies (AGT). He earned his BA degree in Economics from Harvard in 1981. He has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups. Several of his companies were taken public and/or sold to public companies, including one in the medical-technology arena that was sold to Varian, the leading maker of linear accelerators used in cancer therapy. Following his startup experience, he retired to become an Angel Investor in real estate and high tech. He came out of retirement to found and fund AGT after meeting Roscoe Brady at NIH.
About AGT 103-T
AGT103-T is a genetically-modified cell product made from a person's own cells. AGT's approach is unique in that it focuses on repairing the key immune system damage caused by HIV. When HIV infection causes this specific damage, killing of T helper cells required for immunity to HIV, the infected person becomes unable to eliminate the virus and thus, becomes chronically infected. AGT's approach is designed to repair the T helper cell defect and provide durable virus control that is not compromised by HIV strains that vary in sequence or use alternate ways to enter and infect T cells. AGT's AGT103-T HIV therapeutic drug should work to remove infected cells from the body and decrease or eliminate the need for lifelong antiretroviral treatment.
"Previous cell and gene therapies for HIV provided very low doses of critical virus-specific CD4 T cells that are needed to repair the immune defect caused by HIV. AGT103-T becomes highly enriched in these specific cells during our proprietary 12-day manufacturing process. By providing high doses of virus-specific helper T cells, which are protected from HIV damage by a safe genetic modification, AGT's goal is to rebuild the capacity for normal, unhindered immune responses against HIV that may control the infection and protect against future virus exposures. We believe this product will be suitable for persons in different disease stages and with multiple types of HIV infection" explains Chief Science Officer C. David Pauza, PhD.
AGT has entered into a Research Collaboration Agreement with the National Institute of Allergy and Infectious Diseases (NIAID) and was able to demonstrate AGT103-T's mechanism of action. Read about AGT's NIAID Research Collaboration Agreement here.
About American Gene Technologies
American Gene Technologies (AGT) is a gene and cell therapy company with a proprietary gene-delivery platform for rapid development of cell and gene therapies. AGT’s mission is to transform people’s lives by designing highly effective therapeutics to cure infectious diseases, cancers, and inherited disorders. AGT has received three patents for the technology used to make the AGT103-T cell product and ten patents for its unique immuno-oncology approach to stimulate gamma-delta (γδ) T cells to destroy a variety of solid tumors. The company has also developed a synthetic gene for treating Phenylketonuria (PKU), a debilitating inherited disease. AGT's treatment for PKU has been granted Orphan Drug Designation by the Food and Drug Administration (FDA), and it is expected to reach the clinic in 2021.
Follow us on social media for daily updates:
LinkedIn - / 1127234
Twitter - @americangene, / americangene
Facebook - @amerigene, / amerigene
Instagram - @americangenetechnologies, / americangenetechnologies